FDA warns of seizure risk with dalfampridine

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2012年 / 1412卷 / 1期

关键词：

Multiple Sclerosis; Creatinine Clearance; Serum Creatinine Level; Severe Renal Impairment; Product Labelling;

D O I：

10.2165/00128415-201214120-00004

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：2 / 2

相关论文

共 50 条

[1] FDA warns of seizure risk for multiple sclerosis patients who take dalfampridine
不详
[J]. FORMULARY, 2012, 47 (08) : 305 - 305
[2] Clinical overview of the seizure risk of dalfampridine
Haut, Sheryl R.
Bienen, E. Jay
Miller, Aaron
[J]. EXPERT OPINION ON DRUG SAFETY, 2012, 11 (04) : 651 - 657
[3] Dalfampridine Is the Seizure Risk Greater than Previously Thought?
Farag, Amanda
Averill, Allison
[J]. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2013, 92 (07) : 635 - 636
[4] Antidepressants: FDA warns of paediatric suicide risk
[J]. Reactions Weekly, 2003, 976 (1) : 2 - 2
[5] FDA WARNS OF RISK FROM HORMONE PRODUCTS
不详
[J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2018, 253 (08): : 949 - 949
[6] FDA warns of risk of peripheral neuropathy with fluoroquinolones
[J]. Reactions Weekly, 2013, 1466 (1) : 2 - 2
[7] FDA warns of risk of intrathecal injection of tranexamic acid
[J]. Reactions Weekly, 2020, 1835 (1) : 1 - 1
[8] Risk of differentiation syndrome with enasidenib, warns US FDA
[J]. Reactions Weekly, 2018, 1732 (1) : 4 - 4
[9] Vinpocetine during pregnancy: FDA warns of safety risk
[J]. Reactions Weekly, 2019, 1757 (1) : 8 - 8
[10] US FDA warns of increased myopathy risk with Zocor
[J]. Reactions Weekly, 2010, 1294 (1) : 1 - 1

← 1 2 3 4 5 →